Venous Thromboembolism following Two Doses of COVID-19 mRNA Vaccines in the US Population, 2020–2022

The COVID-19 mRNA vaccine is one of the most effective strategies used to fight against COVID-19. Recently, venous thromboembolism (VTE) events after COVID-19 mRNA vaccination have been reported in various research. Such a concern may hamper the ongoing COVID-19 vaccination campaign. Based on the US...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Daoyuan, Zhang, Yan Dora, Lu, Junfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414190/
https://www.ncbi.nlm.nih.gov/pubmed/36016205
http://dx.doi.org/10.3390/vaccines10081317
_version_ 1784775930648985600
author Lai, Daoyuan
Zhang, Yan Dora
Lu, Junfeng
author_facet Lai, Daoyuan
Zhang, Yan Dora
Lu, Junfeng
author_sort Lai, Daoyuan
collection PubMed
description The COVID-19 mRNA vaccine is one of the most effective strategies used to fight against COVID-19. Recently, venous thromboembolism (VTE) events after COVID-19 mRNA vaccination have been reported in various research. Such a concern may hamper the ongoing COVID-19 vaccination campaign. Based on the US Vaccine Adverse Event Reporting System data, this modified self-controlled case series study investigated the association of COVID-19 mRNA vaccination with VTE events among US adults. We found the VTE incidence rate in the recommended dose interval does not change significantly after receiving COVID-19 mRNA vaccines. This conclusion still holds if the analysis is stratified by age and gender. The VTE onset may not be significantly associated with COVID-19 mRNA vaccination.
format Online
Article
Text
id pubmed-9414190
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94141902022-08-27 Venous Thromboembolism following Two Doses of COVID-19 mRNA Vaccines in the US Population, 2020–2022 Lai, Daoyuan Zhang, Yan Dora Lu, Junfeng Vaccines (Basel) Article The COVID-19 mRNA vaccine is one of the most effective strategies used to fight against COVID-19. Recently, venous thromboembolism (VTE) events after COVID-19 mRNA vaccination have been reported in various research. Such a concern may hamper the ongoing COVID-19 vaccination campaign. Based on the US Vaccine Adverse Event Reporting System data, this modified self-controlled case series study investigated the association of COVID-19 mRNA vaccination with VTE events among US adults. We found the VTE incidence rate in the recommended dose interval does not change significantly after receiving COVID-19 mRNA vaccines. This conclusion still holds if the analysis is stratified by age and gender. The VTE onset may not be significantly associated with COVID-19 mRNA vaccination. MDPI 2022-08-15 /pmc/articles/PMC9414190/ /pubmed/36016205 http://dx.doi.org/10.3390/vaccines10081317 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lai, Daoyuan
Zhang, Yan Dora
Lu, Junfeng
Venous Thromboembolism following Two Doses of COVID-19 mRNA Vaccines in the US Population, 2020–2022
title Venous Thromboembolism following Two Doses of COVID-19 mRNA Vaccines in the US Population, 2020–2022
title_full Venous Thromboembolism following Two Doses of COVID-19 mRNA Vaccines in the US Population, 2020–2022
title_fullStr Venous Thromboembolism following Two Doses of COVID-19 mRNA Vaccines in the US Population, 2020–2022
title_full_unstemmed Venous Thromboembolism following Two Doses of COVID-19 mRNA Vaccines in the US Population, 2020–2022
title_short Venous Thromboembolism following Two Doses of COVID-19 mRNA Vaccines in the US Population, 2020–2022
title_sort venous thromboembolism following two doses of covid-19 mrna vaccines in the us population, 2020–2022
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414190/
https://www.ncbi.nlm.nih.gov/pubmed/36016205
http://dx.doi.org/10.3390/vaccines10081317
work_keys_str_mv AT laidaoyuan venousthromboembolismfollowingtwodosesofcovid19mrnavaccinesintheuspopulation20202022
AT zhangyandora venousthromboembolismfollowingtwodosesofcovid19mrnavaccinesintheuspopulation20202022
AT lujunfeng venousthromboembolismfollowingtwodosesofcovid19mrnavaccinesintheuspopulation20202022

Ejemplares similares